Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review.
Cleonisio Leite RodriguesHermany Capistrano de FreitasPaulo Reges Oliveira LimaPedro Helder de Oliveira JuniorJosé Marcelino Aragão FernandesJosé Artur Costa D'AlmeidaPaulo Ribeiro NóbregaPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022)
This is the largest case series of MG exacerbation or myasthenic crisis due to COVID-19 to this date. Mortality was considerably higher than in myasthenic crisis of other etiologies. Previous treatment for MG or acute exacerbation treatment did not seem to interfere with prognosis, although sample size was too small to draw definitive conclusions. Further studies are needed to understand the safety and effectiveness of interventions in this setting, particularly of PLEX, IVIG, rituximab, and tocilizumab.
Keyphrases
- chronic obstructive pulmonary disease
- public health
- coronavirus disease
- sars cov
- myasthenia gravis
- respiratory failure
- systematic review
- rheumatoid arthritis
- liver failure
- physical activity
- radiation therapy
- type diabetes
- squamous cell carcinoma
- cardiovascular events
- cardiovascular disease
- case report
- systemic lupus erythematosus
- drug induced
- replacement therapy
- rectal cancer
- smoking cessation
- locally advanced